Skip to main content

Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.

News

Keep up to date with what is going on at Deepbridge, our investee companies and other exciting news.

Important Notice: Investments in unquoted companies carries high risks and investors could lose all funds invested. Investors should not invest if capital is required in the near term. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Past performance is not a guide to the future performance of an investment, and investors are encouraged to take independent legal, tax and financial advice before considering an investment.
Cambridge
Cambridge United Partners with Mynurva

Mynurva Limited, which is part of the Deepbridge Life Sciences EIS portfolio, has recently partnered with Cambridge United to offer round-the-clock…

Full article
Sky Med Tech
Sky Medical Technology’s Wearable Device Doubles Rate Of Wound Healing

 Sky Medical Technology Ltd, which is part of the Deepbridge Technology Growth EIS portfolio, has recently been featured in an article by Medical…

Full article
Ibis
IbisVision Wins £4.5 Million In Growth Funding

IbisVision, which is part of the Deepbridge Life Sciences EIS portfolio, has recently raised £4.5 million in growth funding as it seeks to open…

Full article
IbisVision
IbisVision Extends NHS Contract

IbisVision, which is part of the Deepbridge Life Sciences EIS portfolio, has recently extended their contract with Forth Valley NHS while their…

Full article
Research
Research reveals advisers prefer EIS to VCT

Deepbridge have recently concluded an adviser survey that suggests financial advisers utilise the Enterprise Investment Scheme (EIS) investment…

Full article
GenoME-Diagnostics
Genome Diagnostics closes £1.4m Funding Round

GenoME Diagnostics, an investee company within Deepbridge's Life Sciences SEIS portfolio has recently closed a £1.4 million funding round which will…

Full article
Enso Tyres
Successful results from Enso Tyres

ENSO Tyres Limited, one of Deepbridge's Technology Growth EIS Companies, has "successfully proven" the benefits of its specially…

Full article
Andrew A
Andrew Aldridge Appointed to EISA Board

The Enterprise Investment Scheme Association (EISA) has appointed Andrew Aldridge (Partner & Chief Marketing Officer at Deepbridge Capital) to…

Full article
EIS Tax year End Opportunities
Tax year End - EIS Opportunities

As we rapidly approach tax year end and clients submit their self-assessment tax returns, financial adviser’s attention will be drawn to tax planning…

Full article
London
IHT Receipits Hit £5.3 Billion

HM Revenue and Customs (HMRC) recorded a £700 Million uptick in Inheritance Tax (IHT) receipts between April and December last year, totalling £5.3…

Full article
AndyRound
Deepbridge Appoints New Senior Investment Director

Deepbridge are pleased to announce the appointment of Dr Andy Round, as Senior Investment Director, within the Deepbridge Life Sciences EIS team.…

Full article
Deepbridge Review 2022
Deepbridge Review 2022

  Image Throughout 2022, the Deepbridge team and I were heavily…

Full article